Streetbeat News

Products Services

CYN

Cyngn Inc. (NASDAQ:CYN) shares surged over 50% following the announcement of a new U.S. patent and a partnership with Alta Equipment Group. The company has been volatile, with shares being halted multiple times. Despite reporting a significant loss last quarter, the stock price has reacted positively to recent developments.

Portfolio Pulse from Vaishali Prayag

July 15, 2024 | 8:15 pm

DIS

Internal communications from Disney's Slack channels have been leaked online by a hacktivist group called Nullbulge. The leaked data includes discussions about ad campaigns, studio technology, and interview candidates, as well as computer code and details about unreleased projects.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:15 pm

WBD

Warner Bros. Discovery Inc's Warner Bros. Games and NetherRealm Studios have unveiled the final DLC character for Mortal Kombat 1, Takeda Takahashi, set for release on July 23. The character will be available initially to Premium Edition or Kombat Pack 1 owners, with broader availability a week later. Future developments for Mortal Kombat 1 are expected to be revealed at San Diego Comic-Con 2024.

Portfolio Pulse from Franca Quarneti

July 15, 2024 | 8:14 pm

KYTX

Kyverna Therapeutics shares are trading higher after the company announced it received FDA Regenerative Medicine Advanced Therapy designation for KYV-101 in the treatment of patients with refractory stiff-person syndrome.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:10 pm

ETON

Eton Pharmaceuticals shares are trading higher following the FDA's acceptance of the New Drug Application for ET-400.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:08 pm

ETON

Eton Pharmaceuticals has received FDA acceptance for its New Drug Application (NDA) for ET-400. The Prescription Drug User Fee Act (PDUFA) target action date is set for February 28, 2025. The product has patent protection through 2043.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:07 pm

KYTX

Kyverna Therapeutics, Inc. announced that its product candidate KYV-101 has received the U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of refractory stiff-person syndrome. This designation will provide Kyverna with expert guidance on efficient drug development and use of surrogate endpoints.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:07 pm

FXI

SPY

The market summary highlights key movements: Trump selects Vance as VP, boosting firearm and prison stocks, while Chinese stocks fall due to weak GDP data.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:04 pm

KOPN

Kopin Corporation and Wilcox Industries have partnered to develop a Modular Dismounted Soldier System, which includes integrated day and night heads-up display optical solutions.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:02 pm

ABVX

Abivax SA (NASDAQ: ABVX) provided an update on its Phase 3 ABTECT trial for obefazimod in ulcerative colitis, which is on track to complete enrollment in early Q1 2025. The company expects top-line results in early Q2 2025 and has sufficient cash to fund operations through Q4 2025. Leadership changes include Sylvie Grégoire as Chair of the Board, Dr. Fabio Cataldi as Chief Medical Officer, and Dr. David Zhang as Chief Strategy Officer.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:01 pm